title: Altered methylation pattern of the G6 PD promoter in Rett syndrome.
abstract: Rett syndrome (RTT) is a neurodevelopmental disorder that almost exclusively affects girls. Recently mutations in MECP2, that encodes the methyl CpG binding protein 2 (MeCP2), have been found to cause RTT. MeCP2 has a role in gene silencing. It binds to methylated cytosine in the DNA and recruits histone deacetylases. We studied the methylation pattern of the promoters of two X chromosomal genes, G6 PD and SYBL1, in patients with RTT and in a control group. Both genes undergo X inactivation which correlates with promoter methylation. A 1 : 1 ratio of methylated versus non-methylated alleles was expected. In the control group a median ratio of 47 : 53 of methylated to non-methylated alleles was found at the G6 PD promoter locus. In 22 patients with RTT the median ratio was significantly different, 33 : 67 (p < 0.0001). Analysis of the SYBL1 promoter revealed an almost identical median ratio of methylated versus non-methylated alleles (RTT 47 : 53; control 49 : 51), however, the range was wider in the RTT group (RTT 23 : 77 to 56 : 44; control 43 : 57 to 55 : 45). There was no apparent correlation between G6 PD promoter methylation status and mutations in the MeCP2 gene or the severity of the clinical phenotype in our patient group. The finding of reduced methylation at the G6 PD promoter is an interesting finding and suggests that there could be widespread dysregulation of X chromosomal genes in Rett syndrome.
authors.affiliation: Neuropediatric Department, Georg-August-Universität Göttingen, Germany. phuppke@med.uni-goettingen.de
authors.forename: P
authors.initials: P
authors.lastname: Huppke
authors.forename: S
authors.initials: S
authors.lastname: Bohlander
authors.forename: N
authors.initials: N
authors.lastname: Krämer
authors.forename: F
authors.initials: F
authors.lastname: Laccone
authors.forename: F
authors.initials: F
authors.lastname: Hanefeld
mesh_terms: D002868:Chromosomal Proteins, Non-Histone; D053938:DNA Fragmentation / Q000235:genetics; D019175:DNA Methylation; D017931:DNA Primers / Q000235:genetics; D004268:DNA-Binding Proteins / Q000235:genetics; D004303:Dosage Compensation, Genetic; D005091:Exons; D005954:Glucosephosphate Dehydrogenase / Q000235:genetics*; D006801:Humans; D008565:Membrane Proteins / Q000235:genetics; D051783:Methyl-CpG-Binding Protein 2; D008780:Methyltransferases / Q000378:metabolism*; D011401:Promoter Regions, Genetic / Q000235:genetics*; D050683:R-SNARE Proteins; D012097:Repressor Proteins; D015518:Rett Syndrome / Q000175:diagnosis / Q000201:enzymology* / Q000235:genetics*; D012720:Severity of Illness Index; D014960:X Chromosome / Q000235:genetics
chemical_list: D002868:Chromosomal Proteins, Non-Histone; D017931:DNA Primers; D004268:DNA-Binding Proteins; C497392:MECP2 protein, human; D008565:Membrane Proteins; D051783:Methyl-CpG-Binding Protein 2; D050683:R-SNARE Proteins; D012097:Repressor Proteins; C121241:VAMP7 protein, human; D005954:Glucosephosphate Dehydrogenase; D008780:Methyltransferases